Description

DIOVAAL 160 MG

Indications

DIOVAAL 160 MG is primarily indicated for the treatment of hypertension and certain types of chronic heart failure. It is also utilized in managing patients with a high risk of cardiovascular events, including those with diabetes and other risk factors. The medication may be prescribed as part of a comprehensive treatment plan that includes lifestyle modifications such as diet and exercise.

Mechanism of Action

DIOVAAL 160 MG contains the active ingredient Valsartan, which is an angiotensin II receptor blocker (ARB). It works by inhibiting the action of angiotensin II, a potent vasoconstrictor that plays a crucial role in regulating blood pressure. By blocking the receptors for angiotensin II, Valsartan causes vasodilation, which leads to a decrease in blood pressure. Additionally, it reduces the secretion of aldosterone, a hormone that promotes sodium and water retention, further aiding in blood pressure control and reducing the workload on the heart.

Pharmacological Properties

DIOVAAL 160 MG exhibits a high degree of specificity for the angiotensin II type 1 (AT1) receptor, with minimal effects on other receptors. This specificity contributes to its efficacy and safety profile. The pharmacokinetics of Valsartan show that it is well absorbed after oral administration, with peak plasma concentrations occurring within 2 to 4 hours. The bioavailability of Valsartan is approximately 25%, and it is primarily eliminated via the liver, with a half-life of about 6 hours, allowing for once-daily dosing in most cases.

Contraindications

DIOVAAL 160 MG is contraindicated in patients with a known hypersensitivity to Valsartan or any of the excipients in the formulation. It should not be used in patients with severe hepatic impairment, biliary obstruction, or renal artery stenosis. Additionally, the medication is contraindicated during pregnancy and lactation due to potential harm to the fetus or nursing infant.

Side Effects

Common side effects associated with DIOVAAL 160 MG include dizziness, fatigue, headache, and gastrointestinal disturbances such as nausea and diarrhea. More serious adverse effects, although rare, may include hypotension, renal impairment, hyperkalemia, and angioedema. Patients should be monitored for these side effects, especially during the initiation of therapy or dose adjustments.

Dosage and Administration

The recommended starting dose of DIOVAAL 160 MG for adults with hypertension is typically 80 mg to 160 mg once daily. For patients with heart failure or those at high cardiovascular risk, the dose may be adjusted based on individual response and tolerability. It is important to take the medication consistently at the same time each day, with or without food. Patients should follow their healthcare provider’s instructions regarding dosage adjustments and should not discontinue the medication abruptly without consulting their provider.

Interactions

DIOVAAL 160 MG may interact with other medications, which can affect its efficacy or increase the risk of adverse effects. Notable interactions include nonsteroidal anti-inflammatory drugs (NSAIDs), which may reduce the antihypertensive effect of Valsartan, and potassium-sparing diuretics or potassium supplements, which can lead to hyperkalemia. Caution should be exercised when DIOVAAL is used in combination with other antihypertensive agents, as it may lead to additive effects and hypotension.

Precautions

Before starting DIOVAAL 160 MG, patients should inform their healthcare provider of their complete medical history, including any renal or hepatic conditions, as well as any current medications. Special caution is warranted in elderly patients, those with a history of hypotension, or those who are dehydrated. Regular monitoring of blood pressure, renal function, and electrolytes is recommended during treatment to ensure safety and efficacy.

Clinical Studies

Clinical studies have demonstrated the efficacy of DIOVAAL 160 MG in reducing blood pressure and improving outcomes in patients with heart failure. In a randomized controlled trial, patients treated with Valsartan showed a significant reduction in systolic and diastolic blood pressure compared to placebo. Furthermore, long-term studies have indicated that Valsartan can reduce the risk of cardiovascular morbidity and mortality in high-risk populations. These findings support its use as a first-line treatment option for hypertension and heart failure.

Conclusion

DIOVAAL 160 MG is an effective medication for managing hypertension and heart failure, offering a well-established mechanism of action and a favorable safety profile. It is important for patients to adhere to their prescribed treatment regimen and to maintain regular follow-up appointments with their healthcare provider to monitor for efficacy and any potential side effects. As with any medication, understanding the benefits and risks associated with DIOVAAL is essential for optimal health outcomes.